Women´s Healthcare

Long experience in research for future innovations

Building on nearly 100 years of experience in the area of hormone research, the research activities of Bayer Schering Pharma in the Women´s Healthcare field, today, concentrate on Female Contraception, Menopause Management and Gynecological Therapies. Their focus are the further development of the active ingredients drospirenone and estradiol as well as new application methods for, for example, contraceptives.

Due to its early basic research, Bayer Schering Pharma has played a major role in the explication of the hormonal regulation of the female reproductive function. Bayer Schering Pharma also participated in the discovery and structural analysis of sex hormones. Already in 1928, Progynon was offered as the first estrogen preparation for the treatment of climacteric disorders. Proluton, the first preparation containing progestin for the prevention of miscarriages, was launched in 1933. Anovlar, the first oral contraceptive, was bought to the market by the former Schering AG. Since then, Bayer Schering Pharma has improved women´s healthcare with innovative gynecological products.

As a research-based pharmaceutical company, Bayer Schering Pharma will continue to utilize its knowledge and experience to offer even better options for contraception and individualized therapies for menopause management. In addition, Bayer Schering Pharma focuses on therapies for gynecological disorders that, yet, cannot be treated sufficiently.